SEC Info  
    Home      Search      My Interests      Help      Sign In      Please Sign In

Integrated Biopharma Inc. – ‘8-K’ for 2/12/24

On:  Monday, 2/12/24, at 4:31pm ET   ·   For:  2/12/24   ·   Accession #:  1437749-24-3763   ·   File #:  1-31668

Previous ‘8-K’:  ‘8-K’ on / for 11/27/23   ·   Next & Latest:  ‘8-K’ on / for 5/10/24

Find Words in Filings emoji
 
  in    Show  and   Hints

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

 2/12/24  Integrated Biopharma Inc.         8-K:2,9     2/12/24   12:246K                                   RDG Filings/FA

Current Report   —   Form 8-K

Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: 8-K         Current Report                                      HTML     43K 
 2: EX-99.1     Exhibit 99.1 Press Release Dated 2 12 2024          HTML     66K 
 7: R1          Document And Entity Information                     HTML     41K 
 9: XML         IDEA XML File -- Filing Summary                      XML     12K 
12: XML         XBRL Instance -- inbp20240209_8k_htm                 XML     13K 
 8: EXCEL       IDEA Workbook of Financial Report Info              XLSX      8K 
 4: EX-101.DEF  XBRL Definitions -- inbp-20240212_def                XML     34K 
 5: EX-101.LAB  XBRL Labels -- inbp-20240212_lab                     XML     43K 
 6: EX-101.PRE  XBRL Presentations -- inbp-20240212_pre              XML     33K 
 3: EX-101.SCH  XBRL Schema -- inbp-20240212                         XSD     14K 
10: JSON        XBRL Instance as JSON Data -- MetaLinks               11±    18K 
11: ZIP         XBRL Zipped Folder -- 0001437749-24-003763-xbrl      Zip     20K 


‘8-K’   —   Current Report


This is an HTML Document rendered as filed.  [ Alternative Formats ]



 iX: 
  inbp20190913_8k.htm  
 C: 
 i false  i 0001016504 0001016504 2024-02-12 2024-02-12
UNITED STATES
 
SECURITIES AND EXCHANGE COMMISSION
 
WASHINGTON, D.C. 20549
 
_________________
 
FORM  i 8-K
 
 
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
 
DATE OF REPORT (DATE OF EARLIEST EVENT REPORTED):
 
 i February 12, 2024
 
________________
 
 i INTEGRATED BIOPHARMA, INC.
(EXACT NAME OF REGISTRANT AS SPECIFIED IN ITS CHARTER)
 
 i Delaware
(STATE OR OTHER JURISDICTION OF INCORPORATION)
 
               
    i 001-31668
  i 22-2407475
(COMMISSION FILE NUMBER)
(I.R.S. EMPLOYER IDENTIFICATION NO.)
 
 i 225 Long Avenue
 i Hillside,  i New Jersey  i 07205
 (ADDRESS OF PRINCIPAL EXECUTIVE OFFICES)
 
 i (973)  i 926-0816
(REGISTRANT’S TELEPHONE NUMBER, INCLUDING AREA CODE)
 
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
 
 i 
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 
 i 
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 
 i 
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 
 i 
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) 
 
 
 
Securities registered pursuant to Section 12(b) of the Exchange Act:
 
Title of each class
Trading Symbol(s)
Name of each exchange on which registered
None
None
None
 
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
 
Emerging growth company  i 
 
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐
     
 
 
 
 
 

 
 
 
Item 2.02. Results of Operations and Financial Condition.
 
On February 12, 2024, Integrated Biopharma, Inc. (the “Company”) issued a press release announcing its financial results for the fiscal quarter ended December 31, 2023.  A copy of the press release is furnished as Exhibit 99.1 hereto and is hereby incorporated by reference into this Item 2.02.
 
The information in this Item 2.02 (including Exhibit 99.1) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.
 
 
Item 9.01 Financial Statements and Exhibits.
 
(d) Exhibits.
 
The following exhibit relating to Item 2.02 shall be deemed to be furnished, and not filed:
 
 
99.1
 
104   Cover Page Interactive Data File (embedded within the Inline XBRL document)
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
-1-

 
 
 
 
EXHIBIT INDEX
 
     
Exhibit
  
Description
   
99.1
  
104   Cover Page Interactive Data File (embedded within the Inline XBRL document)
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
-2-

 
 
 
 
 
SIGNATURE
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
 
  INTEGRATED BIOPHARMA, INC.
   
By:     /s/ Dina L Masi
 
           Dina L Masi
 
           Chief Financial Officer
 
                                   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
-3-

Dates Referenced Herein   and   Documents Incorporated by Reference

This ‘8-K’ Filing    Date    Other Filings
Filed on / For Period end:2/12/2410-Q
12/31/2310-Q
 List all Filings 
Top
Filing Submission 0001437749-24-003763   –   Alternative Formats (Word / Rich Text, HTML, Plain Text, et al.)

Copyright © 2024 Fran Finnegan & Company LLC – All Rights Reserved.
AboutPrivacyRedactionsHelp — Fri., May 17, 10:18:11.1am ET